

Neoadjuvant plus adjuvant dabrafenib and trametinib v
with high-risk, surgically resectable melanoma: a single
phase 2 trial

Lancet Oncology, The
19, 181-193

DOI: [10.1016/s1470-2045\(18\)30015-9](https://doi.org/10.1016/s1470-2045(18)30015-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neo/adjuvant BRAF/MEKi improves outcomes. Nature Reviews Clinical Oncology, 2018, 15, 202-202.	12.5	1
2	Neoadjuvant therapy in melanoma: the next step?. Lancet Oncology, The, 2018, 19, 151-153.	5.1	17
3	Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Letters, 2018, 424, 1-8.	3.2	38
4	Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta OncolÃ³gica, 2018, 57, 1131-1133.	0.8	7
5	Is earlier better for melanoma checkpoint blockade?. Nature Medicine, 2018, 24, 1645-1648.	15.2	28
6	The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities. International Journal of Molecular Sciences, 2018, 19, 3929.	1.8	14
7	Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?. Lancet Oncology, The, 2018, 19, e720-e725.	5.1	25
8	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	15.2	592
9	Neoadjuvant ipilimumab (3Ã¢mg/kg or 10Ã¢mg/kg) and high dose IFN-Î±2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. , 2018, 6, 112.		50
10	Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. Frontiers in Oncology, 2018, 8, 328.	1.3	12
11	Management of Locally and Regionally Recurrent Melanoma. , 2018, , 1-20.		0
12	Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. Cancer Treatment Reviews, 2018, 70, 144-153.	3.4	27
13	The new era of adjuvant therapies for melanoma. Nature Reviews Clinical Oncology, 2018, 15, 535-536.	12.5	73
14	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	0.6	135
15	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35
16	Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. American Journal of Clinical Dermatology, 2018, 19, 639-646.	3.3	1
17	Completion Node Dissection After Sentinel Node Biopsy in Melanoma. JAMA Surgery, 2018, 153, 1045.	2.2	4
18	Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opinion on Orphan Drugs, 2018, 6, 545-551.	0.5	6

#	ARTICLE	IF	CITATIONS
19	Pediatric Melanoma and Atypical Melanocytic Neoplasms. , 2018, , 213-237.		1
20	Immunological effects of BRAF+MEK inhibition. <i>OncImmunity</i> , 2018, 7, e1468955.	2.1	66
21	Management of Locally and Regionally Recurrent Melanoma. , 2019, , 515-534.		0
22	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
23	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3962-3971.	0.7	5
24	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	1.8	27
25	Neoadjuvant therapy of locally/regionally advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986695.	1.4	21
26	Precision Pathology as Part of Precision Medicine: Are We Optimizing Patientsâ€™ Interests in Prioritizing Use of Limited Tissue Samples?. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	8
27	Risk-based stratification in head and neck mucosal melanoma. <i>Oral Oncology</i> , 2019, 97, 44-49.	0.8	13
28	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF</i> ^{V600E} -Mutated Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1036-1043.	2.4	156
29	Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. <i>Drug Resistance Updates</i> , 2019, 45, 13-29.	6.5	82
30	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
31	Current Immunotherapy Practices in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 403-418.	0.6	18
32	Time may Heal All Wounds, but While It Does, Melanoma Marches on. <i>Annals of Surgical Oncology</i> , 2019, 26, 3800-3802.	0.7	1
33	Surgery for Metastatic Melanoma: an Evolving Concept. <i>Current Oncology Reports</i> , 2019, 21, 98.	1.8	11
34	Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. <i>European Journal of Cancer</i> , 2019, 123, 1-10.	1.3	25
35	The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma. <i>Frontiers in Medicine</i> , 2019, 6, 231.	1.2	11
36	The adjuvant treatment revolution for high-risk melanoma patients. <i>Seminars in Cancer Biology</i> , 2019, 59, 283-289.	4.3	40

#	ARTICLE	IF	CITATIONS
37	Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. <i>Cancers</i> , 2019, 11, 1342.	1.7	22
38	Neo-DREAM study investigating Dabrafenib for the treatment of clinical stage IIIb/C melanoma. <i>Future Oncology</i> , 2019, 15, 3665-3674.	1.1	14
39	Adjuvant Therapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 63.	1.3	38
40	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 817-827.	3.3	29
41	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , 2019, 20, 948-960.	5.1	346
42	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIb-c, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 961-971.	5.1	126
43	Neoadjuvant therapy for melanoma: is it ready for prime time?. <i>Lancet Oncology</i> , 2019, 20, 892-894.	5.1	7
44	Prolonged overall survival following metastasectomy in stage IV melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1719-1725.	1.3	10
45	CADM1 is a TWIST1-regulated suppressor of invasion and survival. <i>Cell Death and Disease</i> , 2019, 10, 281.	2.7	37
46	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
47	The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 22.	1.3	8
48	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
49	The emergence of neoadjuvant therapy in advanced melanoma. <i>Melanoma Management</i> , 2019, 6, MMT27.	0.1	12
50	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. <i>Anti-Cancer Drugs</i> , 2019, 30, 1052-1054.	0.7	3
51	The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. <i>Journal of Surgical Research</i> , 2019, 236, 209-215.	0.8	24
52	BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 143-148.	1.9	16
53	Neoadjuvant Treatments for Advanced Resectable Melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 216-221.	0.8	7
54	Updates in adjuvant systemic therapy for melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 222-231.	0.8	35

#	ARTICLE	IF	CITATIONS
55	Adjuvant and Neoadjuvant Treatment of Skin Cancer. Facial Plastic Surgery Clinics of North America, 2019, 27, 139-150.	0.9	8
56	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clinical Cancer Research, 2019, 25, 641-651.	3.2	21
57	Stellenwert der chirurgischen Metastasenentfernung bei Hautmelanomen im Stadium IV. Wiener Medizinische Wochenschrift, 2019, 169, 331-338.	0.5	10
58	Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell and Melanoma Research, 2020, 33, 86-95.	1.5	11
59	Surgical Considerations and Systemic Therapy of Melanoma. Surgical Clinics of North America, 2020, 100, 141-159.	0.5	4
60	Principles of Targeted Therapy for Melanoma. Surgical Clinics of North America, 2020, 100, 175-188.	0.5	40
61	Role of Surgery for Metastatic Melanoma. Surgical Clinics of North America, 2020, 100, 127-139.	0.5	19
62	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Annals of Surgical Oncology, 2020, 27, 2915-2926.	0.7	11
63	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. European Journal of Cancer, 2020, 126, 159-177.	1.3	154
64	Neoadjuvant therapy with vemurafenib in Horner's syndrome as a very rare first diagnosis of a malignant melanoma of unknown primary. JDDG - Journal of the German Society of Dermatology, 2020, 18, 47-49.	0.4	0
65	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. Expert Review of Anticancer Therapy, 2020, 20, 53-62.	1.1	6
66	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World Journal of Surgery, 2020, 44, 1283-1293.	0.8	8
67	Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. Current Opinion in Oncology, 2020, 32, 85-90.	1.1	8
69	Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer. Chinese Medical Journal, 2020, 133, 2444-2455.	0.9	7
70	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579.	0.6	18
71	Recent developments in head and neck melanoma. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 258-262.	0.8	2
72	Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103044.	2.0	29
73	Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect. British Journal of Dermatology, 2021, 185, 253-262.	1.4	20

#	ARTICLE	IF	CITATIONS
74	Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer. <i>Cancer Letters</i> , 2020, 492, 31-43.	3.2	11
75	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. <i>Cancers</i> , 2020, 12, 1994.	1.7	26
76	Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report. <i>Oral Oncology</i> , 2020, 111, 104899.	0.8	0
77	“To Anticipate” Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1941.	1.7	4
78	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
80	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69
81	Updates in the evidence-based management of cutaneous melanoma. <i>Head and Neck</i> , 2020, 42, 3396-3404.	0.9	3
83	Recent advances in the management of anaplastic thyroid cancer. <i>Thyroid Research</i> , 2020, 13, 17.	0.7	39
84	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5068-5077.	3.2	34
85	ASO Author Reflections: The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients: A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2201-2202.	0.7	0
86	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients “ A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
87	Management of Regional Nodal Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 415-431.	0.6	1
88	Neoadjuvant Therapy for Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 445-453.	0.6	2
89	Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. <i>International Journal of Oral Science</i> , 2020, 12, 16.	3.6	108
90	Case report: Neoadjuvant systemic therapy for melanoma. <i>Annals of Medicine and Surgery</i> , 2020, 55, 177-179.	0.5	2
91	Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma. <i>Facial Plastic Surgery</i> , 2020, 36, 186-193.	0.5	5
92	Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2301-2312.	3.3	47
94	The Role of Neoadjuvant Therapy in Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 80.	1.8	8

#	ARTICLE	IF	CITATIONS
95	Adjuvant Therapy for Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 455-465.	0.6	1
96	Adjuvant and neoadjuvant treatment of melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 301-305.	0.3	1
97	Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 10.	1.3	11
98	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	3.0	20
99	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 417.	1.8	32
100	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
101	Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. <i>Cancer Discovery</i> , 2020, 10, 254-269.	7.7	275
102	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413.	1.1	2
103	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
104	Current Management of Melanoma. <i>Updates in Surgery Series</i> , 2021, , .	0.0	0
105	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administrationâ€™Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	3.2	5
106	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
107	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. <i>Annals of Surgical Oncology</i> , 2021, 28, 3512-3521.	0.7	8
108	Applying adjuvant therapy for melanoma into clinical practice. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 129-133.	1.1	1
109	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
110	Practical Management of Melanoma. , 2021, , 241-256.		0
111	Neoadjuvant and Adjuvant Therapies of Melanoma. , 2021, , 401-415.		0
112	Adjuvant Therapy of High-Risk (Stages IIcâ€™IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 637161.	1.3	15

#	ARTICLE	IF	CITATIONS
113	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	15.2	218
114	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. <i>Head and Neck</i> , 2021, 43, 2325-2331.	0.9	6
115	Neoadjuvant Pembrolizumab and High-Dose IFN α -2b in Resectable Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4195-4204.	3.2	18
116	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	2.1	28
117	Overview of Subcutaneous Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 2063.	1.7	0
118	Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 1905.	1.7	7
119	Surgery of small bowel melanoma metastases in the era of efficient medical therapies. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 358-365.	0.6	2
120	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6
121	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
122	The Proportion Cured of Patients with Resected Stage II&III Cutaneous Melanoma in Sweden. <i>Cancers</i> , 2021, 13, 2456.	1.7	2
123	Neoadjuvant Therapy in Resectable Melanoma. <i>Advances in Oncology</i> , 2021, 1, 41-48.	0.1	0
124	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
125	Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. <i>BioScience Trends</i> , 2021, 15, 142-147.	1.1	36
126	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
127	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 670726.	1.3	26
128	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	0.6	22
129	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	3
130	Novel adjuvant options for cutaneous melanoma. <i>Annals of Oncology</i> , 2021, 32, 854-865.	0.6	31

#	ARTICLE	IF	CITATIONS
131	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
132	The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. <i>Nature Communications</i> , 2021, 12, 4098.	5.8	80
133	Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9401.	1.8	16
134	Three Cases of Anorectal Malignant Melanoma Treated with Laparoscopic Abdominoperineal Resection. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 644-656.	0.0	0
135	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
136	Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 871.	1.2	34
137	Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 651-658.	0.7	5
138	Emerging Therapies in the Treatment of Advanced Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 713-733.	0.7	3
139	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 767-793.		1
140	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 775-784.	1.1	268
141	Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. <i>JCI Insight</i> , 2018, 3, .	2.3	216
142	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 2792-2813.	1.2	12
143	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
144	General anaesthesia versus other types of anaesthesia in patients undergoing surgery for treatment of cutaneous melanoma: a systematic review and meta-analysis. <i>European Journal of Dermatology</i> , 2021, 31, 473-485.	0.3	3
145	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIb-IV melanoma: a randomized, open-label, phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1789-1796.	15.2	59
147	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-27.		0
148	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-20.		0
149	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1

#	ARTICLE	IF	CITATIONS
150	Axillary and Epitrochlear Lymph Node Dissection for Melanoma. , 2019, , 1-11.		0
151	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
153	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
154	Skin melanoma. State of the problem. Review. Russian Journal of Oncology, 2019, 24, 113-120.	0.1	0
155	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
156	Cutaneous Melanoma – A Review of Systemic Therapies. Acta Dermato-Venereologica, 2020, 100, adv00141.	0.6	7
157	Axillary and Epitrochlear Lymph Node Dissection for Melanoma. , 2020, , 657-667.		0
159	Management of Melanoma Patients with Positive Nodes. Advances in Surgery, 2020, 54, 191-204.	0.6	0
161	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
162	Surgery-mediated tumor-promoting effects on the immune microenvironment. Seminars in Cancer Biology, 2022, 86, 408-419.	4.3	29
163	Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. British Journal of Surgery, 2022, 109, 489-492.	0.1	17
164	Targeting MAPK in recurrent, low-grade serous ovarian cancer. Lancet, The, 2022, 399, 499-501.	6.3	3
165	Case of preauricular primary malignant melanoma treated with preoperative dabrafenib/trametinib. Skin Cancer, 2021, 36, 203-211.	0.1	0
166	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210830.	1.4	13
167	25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions. Current Oncology Reports, 2022, 24, 533-542.	1.8	3
169	Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials. Journal of Surgical Oncology, 2022, 125, 38-45.	0.8	1
170	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. Cancers, 2022, 14, 110.	1.7	5
171	Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers, 2022, 14, 81.	1.7	5

#	ARTICLE	IF	CITATIONS
172	Melanoma management in the 21st century: a change in paradigm. ANZ Journal of Surgery, 2021, 91, 2557-2558.	0.3	0
176	Neoadjuvant therapy for melanoma: new and evolving concepts.. Clinical Advances in Hematology and Oncology, 2022, 20, 47-55.	0.3	0
177	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 315-324.	0.4	2
178	Future Treatments in Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 325-331.	0.4	1
179	The future of targeted kinase inhibitors in melanoma. , 2022, 239, 108200.		17
181	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	13.7	54
182	DNA Methylation-Specific Analysis of G Protein-Coupled Receptor-Related Genes in Pan-Cancer. Genes, 2022, 13, 1213.	1.0	2
183	Educational Review: Neoadjuvant Approaches to Melanoma. Annals of Surgical Oncology, 2022, 29, 8492-8500.	0.7	4
184	Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation. Frontiers in Oncology, 0, 12, .	1.3	1
185	Neoadjuvant immunotherapy of locoregionally advanced solid tumors. , 2022, 10, e005036.		9
186	Fifty years of progress in surgical oncology: Melanoma. Journal of Surgical Oncology, 2022, 126, 888-895.	0.8	0
187	Cambios histopatológicos secundarios a terapia diana en melanoma. Actas Dermo-sifilográficas, 2022, 114, 75-75.	0.2	0
188	Neoadjuvant therapy for melanoma: A critical appraisal. Journal of Surgical Oncology, 0, , .	0.8	0
189	Regional control after precision lymph node dissection for clinically evident melanoma metastasis. Journal of Surgical Oncology, 0, , .	0.8	1
190	Systemic adjuvant therapy for high-risk cutaneous melanoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211340.	1.4	7
191	Targeted Therapy and Immunotherapy in Melanoma. Dermatologic Clinics, 2023, 41, 65-77.	1.0	14
192	Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives. Advances in Anatomic Pathology, 2023, 30, 218-229.	2.4	2
193	Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature, 2022, 611, 155-160.	13.7	114

#	ARTICLE	IF	CITATIONS
195	Neoadjuvant treatment for stage III and IV cutaneous melanoma. The Cochrane Library, 2023, 2023, .	1.5	1
196	Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211489.	1.4	2
197	Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Frontiers in Medicine, 0, 9, .	1.2	6
198	Checkpoint blockade and <scp>BRAF</scp>/<scp>MEK</scp> therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998â€2009 and 2010â€2017. International Journal of Cancer, 2023, 153, 380-388.	2.3	0
199	Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review. European Journal of Cancer, 2023, 184, 83-105.	1.3	3
200	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
201	Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. Frontiers in Oncology, 0, 13, .	1.3	1
202	Neoadjuvant Therapy in Melanoma: Where Are We Now?. Current Oncology Reports, 2023, 25, 325-339.	1.8	0
203	Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene. Melanoma Research, 2023, 33, 247-251.	0.6	3
204	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers, 2023, 15, 1766.	1.7	6
206	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nature Reviews Clinical Oncology, 2023, 20, 408-422.	12.5	9
223	Neoadjuvant therapy for resectable melanoma. Clinical and Experimental Metastasis, 0, , .	1.7	0